Addario Lung Cancer Consortium
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2008
- Initiating Organization: Addario Lung Cancer Medical Institute
- Initiator Type: Nonprofit foundation
- Disease focus:
Lung Cancer - Location: Europe
Abstract
Addario Lung Cancer Medical Institute (ALCMI) is a patient-centric, international research consortium. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 20+ institutions in the U.S. and Europe, supported by dedicated research infrastructures such as centralized tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through their network of community cancer centers – accelerating novel research advancements to Lung Cancer patients.
Mission
The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. Patients fighting Lung Cancer today and those who will be diagnosed tomorrow are at the heart of their mission. Driven by the knowledge that Lung Cancer is the number one cancer killer worldwide annually, their imperative is to dramatically increase patient survival rate. Their ultimate goal is to be the global leader fighting Lung Cancer and the largest source of non-profit funding dedicated to turning Lung Cancer into a manageable, chronic disease and ultimately, a curable disease.
Consortium History
CASTLE (2010-present): established standardized biorepository with outcomes data for improved understanding of tumor biology, and molecular drivers (free testing). It also serves as a collaboration engine driving discovery, development and delivery of diagnostics, targeted therapies, and immuno-oncology agents.
INHERIT EGFR (2012-present): determining prevalence of inherited EGFR T790 mutations (free testing) in lung cancer patients and their first-degree relatives and estimating prevalence of CAT scan detected lung nodules in individuals with inherited mutations and no lung cancer diagnosis
Genomics of Young Lung Cancer (2014-present): facilitating delivery of targeted therapies, characterizing the impact of young age at lung cancer diagnosis on the genomic landscape of lung cancer (free testing), and establishing a prospective registry of biospecimens for investigational acquired and inherited genomics.
Structure & Governance
The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”) works in tandem with their partner, the Addario Lung Cancer Foundation (ALCF). ALCMI is patient founded, focused, and funded.
Financing
Since its founding in 2006, the ALCF has grown into the first international collaborative entity of its kind, raising over $30 million for Lung Cancer research through a variety of fundraising campaigns and initiatives. ALCMI was founded 2 years later in 2008.
Patient Engagement
Patients benefit by being empowered through more active involvement and participation in advancing discovery, treatment and care for themselves and others. By participating in clinical research and giving researchers access to their biospecimens, clinical data, and therapeutic outcomes, patients will help to accelerate the development of precision medicine for lung cancer.
Links/Social Media Feed
Homepage |
http://www.lungcancerfoundation.org/research/alcmi/ |
Points of Contact
Steven Young, President & COO / (203) 226-5765 / syoung@alcmi.net
Samantha Cummis, Director of Marketing and Communications, samantha@lungcancerfoundation.org.
Sponsors & Partners
Astellas Pharma US |
Biodesix |
Boehringer Ingelheim |
Bristol-Myers Squibb |
CancerCURE of America |
Caris Life Science |
Celgene |
Genentech – A Member of the Roche Group |
GTx |
Helsinn |
Ignyta |
Life Technologies |
Palo Alto Medical Foundation – Sutter Health |
PenTV |
Pfizer Oncology |
Project Hope Exchange |
RadiologyInfo.org |
The Safeway Foundation |
SuperDimension |